These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2983121)

  • 21. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).
    Uhlig H; Rutter G; Dernick R
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2809-12. PubMed ID: 6198443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postabsorption neutralization of poliovirus.
    Vrijsen R; Mosser A; Boeyé A
    J Virol; 1993 Jun; 67(6):3126-33. PubMed ID: 8388493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
    Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
    Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies.
    Emini EA; Kao SY; Lewis AJ; Crainic R; Wimmer E
    J Virol; 1983 May; 46(2):466-74. PubMed ID: 6188863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to poliovirus detected by immunoradiometric assay with a monoclonal antibody.
    Spitz M; Fossati CA; Schild GC; Spitz L; Brasher M
    J Virol Methods; 1982 Oct; 5(2):101-11. PubMed ID: 6296172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
    Taniguchi K; Urasawa S; Urasawa T
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strain differentiation of polioviruses with monoclonal antibodies.
    Osterhaus AD; van Wezel AL; Stegmann AJ; van Asten JA; Hazendonk AG
    Dev Biol Stand; 1984; 57():135-9. PubMed ID: 6098494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.
    Icenogle J; Gilbert SF; Grieves J; Anderegg J; Rueckert R
    Virology; 1981 Nov; 115(1):211-5. PubMed ID: 6270899
    [No Abstract]   [Full Text] [Related]  

  • 30. Structural studies of virus-antibody immune complexes (poliovirus type I): Characterization of the epitopes in 3D.
    Bannwarth L; Girerd-Chambaz Y; Arteni AA; Guigner JM; Lemains J; Ronzon F; Manin C; Vénien-Bryan C
    Mol Immunol; 2015 Feb; 63(2):279-86. PubMed ID: 25146483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments.
    Colonno RJ; Callahan PL; Leippe DM; Rueckert RR; Tomassini JE
    J Virol; 1989 Jan; 63(1):36-42. PubMed ID: 2535737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated activation of Sindbis virus.
    Flynn DC; Olmsted RA; Mackenzie JM; Johnston RE
    Virology; 1988 Sep; 166(1):82-90. PubMed ID: 3413988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies reveal in blocking reactions the antigenicity and antibody response of poliovirus.
    Uhlig H; Rutter G; Dernick R
    Dev Biol Stand; 1984; 57():187-91. PubMed ID: 6084610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
    van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
    Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
    Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capsid destabilization is required for antibody-mediated disruption of poliovirus.
    Delaet I; Boeyé A
    J Gen Virol; 1994 Mar; 75 ( Pt 3)():581-7. PubMed ID: 8126454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
    Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
    Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.